Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914

NCT00041899 | Completed Phase 1

• 2 other identifiers: 02021902-CH-0219
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

This study will compare blood levels of the drug CDB-2914 in healthy women receiving the compound in crystalline powder form with the blood levels of women receiving an identical dose of the drug in micronized form. Generally, absorption of compounds made into a crystalline powder is less than that of micronized compounds, in which the substance is processed into many similar-sized particles. CDB-2914 is a manmade hormone similar to the hormones cortisol and progesterone. The National Institute of Child Health and Human Development is evaluating the ability of this drug to treat reproductive conditions. Institute studies have shown that CDB-2914 can increase the time to produce a mature egg in the ovary, and cause an early menstrual period, CDB-2914 might be used to treat fibroids and endometriosis pain. As part of its evaluation for these purposes, this study will determine if absorption of crystalline and micronized powder forms of CDB-2914 result in the same blood levels of the drug. Women between 18 and 50 years of age who are in good health may be eligible for this study. Premenopausal women must not be pregnant (as determined by a urine pregnancy test) or breastfeeding and must practice birth control during the study. Candidates will be screened with a medical history, physical examination, and blood and urine tests. Women who use an IUD for contraception are advised to also use a barrier contraceptive (diaphragm or condom) the week after taking CDB-2914. Participants will be admitted to the NIH Clinical Center inpatient service or the outpatient day hospital twice for pharmacokinetic studies (blood drawing to measure blood levels of CDB-2914 after a single dose of the drug). They will come to the Clinical Center at 7:00 a.m. and have a catheter (thin plastic tube) inserted into an arm vein for drawing blood for the first 24 hours of the study. Eight milliliters (about 2 teaspoons) of blood will be drawn 5 minutes and 1 minute before taking CDB-2914 (in either crystalline or micronized powder form) and then at the following times after taking the drug: 15, 30, 45, 60, 75, 90, 105, 120, 150 and 180 minutes (3 hours), and 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 hours (5 days). Participants will take all their meals in the day hospital or ward during the first 26 hours of sampling. Inpatients will leave the hospital after the 24-hour blood draw and return as an outpatient on days 2 through 5. At the 48-hour time point, additional blood will be drawn to check blood counts and chemistries, and for liver and kidney function tests.

Conditions

Healthy

Keywords

Progesterone; Cortisol; Menstrual Cycle; Formulation; Endometrium; Estrogen

Interventions

CDB-2914 DRUG

COB-2914 DRUG

Eligibility Criteria

• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Female gender--to evaluate effects in the target population for clinical trials.
• In good health. Chronic medication use is acceptable except for glucocorticoid use. Other chronic medication use may be acceptable at discretion of the principal investigator. Interval use of over-the-counter drugs is acceptable but must be recorded.
• Hemoglobin greater than 10 g/dL.
• Willing and able to comply with study requirements.
• Age 18 to 50.
• Using mechanical (condoms, diaphragms), abstinence, oral contraceptive, IUD or sterilization methods of contraception for the duration of the study. Because the effect of CDB-2914 on IUD efficacy is not known, women using this form of birth control will be advised to use barrier methods during the cycle(s) in which they participate.
• Negative urine pregnancy test within one week of the first study. If the second study occurs in a subsequent cycle, the pregnancy test will be repeated.

You may not qualify if:

• Significant abnormalities in the history, physical or laboratory examination
• Pregnancy
• Lactation
• Use of oral, injectable or inhaled glucocorticoids or megesterol within the last year
• Unexplained vaginal bleeding
• History of malignancy within the past 5 years
• Use of anti-epileptic agents

Sponsors & Collaborators

• Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): lead

Study Sites (1)

National Institute of Child Health and Human Development (NICHD)

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

• Batista MC, Cartledge TP, Zellmer AW, Merino MJ, Axiotis C, Loriaux DL, Nieman LK. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy. Am J Obstet Gynecol. 1992 Jul;167(1):60-5. doi: 10.1016/s0002-9378(11)91627-5.

  PMID: 1442957 BACKGROUND

• Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med. 1997;48:129-56. doi: 10.1146/annurev.med.48.1.129.

  PMID: 9046951 BACKGROUND

• D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979 Mar;9(2):115-34. doi: 10.1016/0010-468x(79)90025-4.

  PMID: 761456 BACKGROUND

MeSH Terms

Interventions

ulipristal

Study Design

• Study Type: interventional
• Phase: phase 1
• Purpose: TREATMENT
• Sponsor Type: NIH

Study Record Dates

• First Submitted: July 18, 2002
• First Posted: July 19, 2002
• Study Start: May 1, 2002
• Study Completion: March 1, 2005
• Last Updated: March 4, 2008

Record last verified: 2005-03

Locations

US (1)